Stelzer Laurie
SEC-identified person · CIK 1644348 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Sionna Therapeutics, Inc. SION | Director | filed 2025–2026 |
| PMV Pharmaceuticals, Inc. PMVP | Director | filed 2020–2026 |
| MBX Biosciences, Inc. MBX | Director | filed 2026–2026 |
| Spyre Therapeutics, Inc. SYRE | Director | filed 2023–2026 |
| Mirati Therapeutics, Inc. mrtx | Chief Financial Officer | filed 2022–2023 |
| Surface Oncology, Inc. SURF | Director | filed 2018–2022 |
| Arena Pharmaceuticals INC ARNA | EVP & Chief Financial Officer | filed 2020–2022 |
| Halozyme Therapeutics, INC. Halo | SVP, Chief Financial Officer | filed 2015–2020 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.